全文获取类型
收费全文 | 34178篇 |
免费 | 2436篇 |
国内免费 | 56篇 |
专业分类
耳鼻咽喉 | 319篇 |
儿科学 | 1217篇 |
妇产科学 | 1031篇 |
基础医学 | 4387篇 |
口腔科学 | 453篇 |
临床医学 | 4475篇 |
内科学 | 6219篇 |
皮肤病学 | 492篇 |
神经病学 | 3592篇 |
特种医学 | 633篇 |
外国民族医学 | 4篇 |
外科学 | 3112篇 |
综合类 | 364篇 |
一般理论 | 45篇 |
预防医学 | 4728篇 |
眼科学 | 515篇 |
药学 | 2241篇 |
中国医学 | 24篇 |
肿瘤学 | 2819篇 |
出版年
2024年 | 44篇 |
2023年 | 296篇 |
2022年 | 521篇 |
2021年 | 1130篇 |
2020年 | 691篇 |
2019年 | 1049篇 |
2018年 | 1169篇 |
2017年 | 839篇 |
2016年 | 995篇 |
2015年 | 1020篇 |
2014年 | 1348篇 |
2013年 | 1902篇 |
2012年 | 2777篇 |
2011年 | 3001篇 |
2010年 | 1562篇 |
2009年 | 1318篇 |
2008年 | 2404篇 |
2007年 | 2412篇 |
2006年 | 2205篇 |
2005年 | 2084篇 |
2004年 | 1860篇 |
2003年 | 1602篇 |
2002年 | 1626篇 |
2001年 | 231篇 |
2000年 | 206篇 |
1999年 | 235篇 |
1998年 | 318篇 |
1997年 | 245篇 |
1996年 | 175篇 |
1995年 | 192篇 |
1994年 | 146篇 |
1993年 | 127篇 |
1992年 | 96篇 |
1991年 | 72篇 |
1990年 | 61篇 |
1989年 | 65篇 |
1988年 | 64篇 |
1987年 | 55篇 |
1986年 | 57篇 |
1985年 | 48篇 |
1984年 | 37篇 |
1983年 | 40篇 |
1982年 | 32篇 |
1981年 | 33篇 |
1980年 | 29篇 |
1979年 | 24篇 |
1978年 | 24篇 |
1977年 | 18篇 |
1976年 | 18篇 |
1972年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
171.
Lisa Hamilton Martin Blackstein Terri Berk Robin S. McLeod Steven Gallinger Lisa Madlensky Zane Cohen 《Canadian journal of surgery》1996,39(3):247-252
Objective
To determine the efficacy of chemotherapy for inoperable desmoid tumours associated with familial adenomatous polyposis.Design
A review of three cases of unresectable desmoid tumours and of the literature on the subject.Setting
The Steven Atanas Stavro Polyposis Registry at Mount Sinai Hospital in Toronto.Patients
Three patients with symptomatic, unresectable desmoid tumours associated with familial adenomatous polyposis and unresponsive to conventional hormone therapy.Intervention
A chemotherapy regimen of seven cycles of doxorubicin (dose ranging from 60 to 90 mg/m2) and dacarbazine (1000 mg/m2), followed by carboplatin (400 mg/m2) and dacarbazine.Outcome Measures
Clinical improvement and tumour regression demonstrated by computed tomography.Results
In each of the three cases significant tumour regression was seen clinically and radiologically.Conclusions
Cytotoxic chemotherapy is an effective treatment for desmoid tumours associated with familial adenomatous polyposis. The chemotherapy should be started early in cases of symptomatic desmoid tumour unresponsive to conventional medical therapy. 相似文献172.
Purpose
The anatomical pattern of recurrence and metastases in patients with urothelial cancer are described, and the relationship between treatment and features of the primary invasive tumor and the subsequent pattern of metastases is analyzed.Materials and Methods
Between 1976 and 1991, 240 patients with recurrent or metastatic urothelial cancer were admitted to our department.Results
The majority of the patients had recurrence within 2 years after initial diagnosis. Local recurrences and lung metastases were diagnosed significantly earlier than other metastases. Multiple sites were involved in more than half of the patients. The most common sites of recurrence were local in the bladder in 65 percent of the cases and bone in 35 percent, followed by lymph nodes in 26 percent and lung in 20 percent. The pattern of metastases was similar in patients with different histological findings, grade and location of the primary tumor. Patients younger than 60 years and those with cancer of the renal pelvis more often had distant metastases compared to older patients with bladder cancer. Local recurrences were less frequent in patients who had undergone cystectomy compared to those treated with radiotherapy only. Moreover, patients with local recurrences were likely to have metastases elsewhere.Conclusions
Bone was the most frequent site of metastases outside the pelvis and all patients suspected to have recurrence should be examined for bone metastases. The results indicate that the pattern of recurrence and metastases are not dependent on the features of the primary tumor. 相似文献173.
Background: The pharmacokinetic variables of drug clearance and volume of distribution are usually corrected for body weight
or surface area. Only recently have the relationships which exist between body size, physiologic function and pharmacokinetic
variables been evaluated in the obese population. These effects are not widely known, and data on this and the effects of
bariatric surgical procedures are scantily documented in the surgical literature. Methods: Literature review. Results: Drugs
with a low or moderate affinity for adipose tissue have a moderate increase in the volume of distribution (Vd), and this correlates
with the increase in lean body mass (LBM). Highly lipophilic drugs, with some exceptions, show the expected increase in Vd
and prolongation of elimination half-life, indicating a marked distribution into adipose tissue. Drug absorption, in general,
is slowed by delayed gastric emptying and is normal when gastric emptying is normal or increased. Most drug absorption occurs
in the small intestine where duration of drug/mucosal contact is the most important factor. Conclusions: Drugs whose distribution
is restricted to LBM should utilize a loading dose based on ideal body weight (IBW). For those drugs which distribute freely
into adipose tissue, the loading dose should be based on total body weight (TBW). Adjustment of the maintenance dose depends
on clearance rates. In a few cases dosage adjustment depends on pharmacodynamic data, since drug clearance does not conform
to these recommendations, for reasons which remain to be defined. Following bariatric surgery, in the absence of delayed gastric
emptying or uncontrolled diarrhea, drug absorption rates are usually comparable to the non-operated patient. 相似文献
174.
Lisa A. Musmanno Robert S. Jamison Richard S. Barnett Edward Buford Jeffrey N. Davidson 《Somatic Cell and Molecular Genetics》1992,18(4):309-318
The mammalianCAD gene codes for a 240-kDa multifunctional protein that catalyzes the first three steps of de novo pyrimidine biosynthesis. Previously, the longest cDNA construct available was missing approximately 500 bp of coding sequence at the 5 end, thereby lacking the sequence to encode the entire carbamylphosphate synthetase (CPSase) domain. Here, a completeCAD hamster cDNA is constructed, placed into a mammalian expression vector, and transfected into hamster cells deficient in CAD. Transfectants show coordinately restored levels of all three enzyme activities and the presence of full-length CAD protein. A derivative construct of theCAD cDNA was generated that should encode only the CPSase domain. When transfected into mammalian cells, a protein was synthesized that had significant CPSase activity both in vivo and in vitro. The two constructs generated in this study will facilitate the study of CAD structure, function, and allosteric regulation. 相似文献
175.
In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. 总被引:10,自引:0,他引:10
Kiran C Patki Lisa L Von Moltke David J Greenblatt 《Drug metabolism and disposition》2003,31(7):938-944
Midazolam, triazolam (TRZ), testosterone, and nifedipine have all been widely used as probes for in vitro metabolism of CYP3A. We used these four substrates to assess the contributions of CYP3A4 and CYP3A5 to in vitro biotransformation in human liver microsomes (HLMs) and in recombinant enzymes. Recombinant CYP3A4 and CYP3A5 (rCYP3A4 and rCYP3A5) both produced 1-OH and 4-OH metabolites from midazolam and triazolam, 6 beta-hydroxytestosterone from testosterone, and oxidized nifedipine from nifedipine. Overall, the metabolic activity of CYP3A5 was less than that of CYP3A4. Ketoconazole potently inhibited midazolam, triazolam, testosterone, and nifedipine metabolite formation in HLMs and in rCYP3A4. The inhibitory potency of ketoconazole in rCYP3A5 was about 5- to 19-fold less than rCYP3A4 for all four substrates. In testosterone interaction studies, testosterone inhibited 1-OH-TRZ formation, but significantly activated 4-OH-TRZ formation in HLMs and rCYP3A4 but not in rCYP3A5. Oxidized nifedipine formation was inhibited by testosterone in rCYP3A4. However, in rCYP3A5, testosterone slightly activated oxidized nifedipine formation at lower concentrations, followed by inhibition. Thus, CYP3A4 and CYP3A5 both contribute to midazolam, triazolam, testosterone, and nifedipine biotransformation in HLMs, with CYP3A5 being metabolically less active than CYP3A4 in general. Because the inhibitory potency of ketoconazole in rCYP3A5 is substantially less than in rCYP3A4 and HLMs, CYP3A5 is probably less important than CYP3A4 in drug-drug interactions involving ketoconazole and CYP3A substrates. 相似文献
176.
Soundararajan Krishnaswamy Su X Duan Lisa L Von Moltke David J Greenblatt Michael H Court 《Drug metabolism and disposition》2003,31(1):133-139
Investigation of human UDP-glucuronosyltransferase (UGT) isoforms has been limited by a lack of specific substrate probes. In this study serotonin was evaluated for use as a probe substrate for human UGT1A6 using recombinant human UGTs and tissue microsomes. Of the 10 commercially available recombinant UGT isoforms, only UGT1A6 catalyzed serotonin glucuronidation. Serotonin-UGT activity at 40 mM serotonin concentration varied more than 40-fold among human livers (n = 54), ranging from 0.77 to 32.9 nmol/min/mg of protein with a median activity of 7.1 nmol/min/mg of protein. Serotonin-UGT activity kinetics of representative human liver microsomes (n = 7) and pooled human kidney, intestinal and lung microsomes and recombinant human UGT1A6 typically followed one enzyme Michaelis-Menten kinetics. Serotonin glucuronidation activity in these human liver microsomes had widely varying V(max) values ranging from 0.62 to 51.3 nmol/min/mg of protein but very similar apparent K(m) values ranging from 5.2 to 8.8 mM. Pooled human kidney, intestine, and lung microsomes had V(max) values (mean +/- standard error of the estimates) of 8.8 +/- 0.4, 0.22 +/- 0.00, and 0.03 +/- 0.00 nmol/min/mg of protein (respectively) and apparent K(m) values of 6.5 +/- 0.9, 12.4 +/- 2.0, and 4.9 +/- 3.3 mM (respectively). In comparison, recombinant UGT1A6 had a V(max) of 4.5 +/- 0.1 nmol/min/mg of protein and an apparent K(m) of 5.0 +/- 0.4 mM. A highly significant correlation was found between immunoreactive UGT1A6 protein content and serotonin-UGT activity measured at 4 mM serotonin concentration in human liver microsomes (R(s) = 0.769; P < 0.001) (n = 52). In conclusion, these results indicate that serotonin is a highly selective in vitro probe substrate for human UGT1A6. 相似文献
177.
Serum protein profiles to identify head and neck cancer. 总被引:19,自引:0,他引:19
J Trad Wadsworth Kenneth D Somers Lisa H Cazares Gunjan Malik Bao-Ling Adam Brendan C Stack George L Wright O John Semmes 《Clinical cancer research》2004,10(5):1625-1632
PURPOSE: New and more consistent biomarkers of head and neck squamous cell carcinoma (HNSCC) are needed to improve early detection of disease and to monitor successful patient management. The purpose of this study was to determine whether a new proteomic technology could correctly identify protein expression profiles for cancer in patient serum samples. EXPERIMENTAL DESIGN: Surface-enhanced laser desorption/ionization-time of flight-mass spectrometry ProteinChip system was used to screen for differentially expressed proteins in serum from 99 patients with HNSCC and 102 normal controls. Protein peak clustering and classification analyses of the surface-enhanced laser desorption/ionization spectral data were performed using the Biomarker Wizard and Biomarker Patterns software (version 3.0), respectively (Ciphergen Biosystems, Fremont, CA). RESULTS: Several proteins, with masses ranging from 2778 to 20800 Da, were differentially expressed between HNSCC and the healthy controls. The serum protein expression profiles were used to develop and train a classification and regression tree algorithm, which reliably achieved a sensitivity of 83.3% and a specificity of 100% in discriminating HNSCC from normal controls. CONCLUSIONS: We propose that this technique has potential for the development of a screening test for the detection of HNSCC. 相似文献
178.
Clinton F Stewart Lisa C Iacono Murali Chintagumpala Stewart J Kellie David Ashley W C Zamboni M N Kirstein Maryam Fouladi Louis G Seele Dana Wallace Peter J Houghton Amar Gajjar 《Journal of clinical oncology》2004,22(16):3357-3365
PURPOSE: To assess the antitumor efficacy of pharmacokinetically guided topotecan dosing in previously untreated patients with medulloblastoma and supratentorial primitive neuroectodermal tumors, and to evaluate plasma and CSF disposition of topotecan in these patients. PATIENTS AND METHODS: After maximal surgical resection, 44 children with previously untreated high-risk medulloblastoma were enrolled, of which 36 were assessable for response. The topotecan window consisted of two cycles, administered initially as a 30-minute infusion daily for 5 days, lasting 6 weeks. Pharmacokinetic studies were conducted on day 1 to attain a topotecan lactone area under the plasma concentration-time curve (AUC) of 120 to 160 ng/mL.h. After 10 patients were enrolled, the infusion was modified to 4 hours, with dosage individualization. RESULTS: Of 36 assessable patients, four patients (11.1%) had a complete response and six (16.6%) showed a partial response, and disease was stable in 17 patients (47.2%). Toxicity was mostly hematologic, with only one patient experiencing treatment delay. The target plasma AUC was achieved in 24 of 32 studies (75%) in the 30-minute infusion group, and in 58 of 93 studies (62%) in the 4-hour infusion group. The desired CSF topotecan exposure was achieved in seven of eight pharmacokinetic studies when the topotecan plasma AUC was within target range. CONCLUSION: Topotecan is an effective agent against pediatric medulloblastoma in patients who have received no therapy other than surgery. Pharmacokinetically guided dosing achieved the target plasma AUC in the majority of patients. This drug warrants testing as part of standard postradiation chemotherapeutic regimens. Furthermore, these results emphasize the importance of translational research in drug development, which in this case identified an effective drug. 相似文献
179.
Lisa Licitra Paolo Bossi Laura Locati Franco Zunino 《Journal of clinical oncology》2004,22(2):377; author reply 377-377; author reply 378
180.
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. 总被引:3,自引:0,他引:3
Jeffrey L Evelhoch Patricia M LoRusso Zhanquan He Zachary DelProposto Lisa Polin Thomas H Corbett Peter Langmuir Catherine Wheeler Andrew Stone Joanna Leadbetter Anderson J Ryan David C Blakey John C Waterton 《Clinical cancer research》2004,10(11):3650-3657
PURPOSE: ZD6126 is a novel vascular targeting agent currently undergoing clinical evaluation. It acts by destabilizing the microtubulin of fragile and proliferating neoendothelial cells in tumors. The drug leads to blood vessel congestion, the selective destruction of the vasculature, and extensive necrosis in experimental tumors. The aim of the study reported here was to assess the ability of dynamic contrast enhanced magnetic resonance imaging (MRI) to measure the antivascular effects of ZD6126 in tumors. EXPERIMENTAL DESIGN: The work was carried out in mice bearing C38 colon adenocarcinoma and in patients with advanced cancers. MRI was performed before and 6 h (human tumors) or 24 h (C38 tumors) after i.v. drug administration. Contrast agent (gadolinium diethylenetriaminepentaacetate) enhancement was characterized by the initial area under the gadolinium diethylenetriaminepentaacetate uptake versus time curve (IAUC). IAUC reflects blood flow, vascular permeability, and the fraction of interstitial space. RESULTS: The median IAUC was reduced in all C38 tumors after ZD6126 administration [by 6-48% at 50 mg/kg (n = 3)], 58-91% at 100 mg/kg (n = 4), and 11-93% at 200 mg/kg (n = 6). In contrast, the administration of vehicle only led to no consistent change in median IAUC (n = 4). The ZD6126-induced changes in median IAUC appeared to be dose dependent (P = 0.045). No ZD6126-induced changes were apparent in murine muscle. Similar effects were seen in preliminary data from human tumors (11 tumors studied, 9 patients). At doses of 80 mg/m(2) and higher, the median IAUC post-ZD6126 treatment was reduced in all of the tumors studied (8 tumors, 6 patients) to 36-72% from the baseline value. There was a significant trend of increasing reductions with increasing exposure (P < 0.01). No drug-induced changes in human muscle or spleen IAUC were apparent. The reproducibility of the median IAUC parameter was investigated in patients. In 19 human tumors (measured in 19 patients) inter- and intratumor coefficients of variation were 64 and 18%. CONCLUSIONS: The contrast enhanced-MRI measured median IAUC is a useful end point for quantifying ZD6126 antivascular effects in human tumors. 相似文献